Key facts
- This page summarizes Sandip I. Patel's Form 4 filing for Peak Bio, Inc..
- 7 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 18 Nov 2024, 18:55.
Sandip I. Patel - 14 Nov 2024 Form 4 Insider Report for Peak Bio, Inc.
- Reporting relationship
- Director
- Issuer ticker
- N/A
- Reported as of
- 14 Nov 2024
- Net transaction value
- -$275,500
- SEC form
- 4
- Accepted by SEC
- 18 Nov 2024, 18:55:45 UTC
- Prior SEC filing
- 16 Feb 2024
- Next SEC filing
- 24 Mar 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Sandip Patel
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Sandip I. Patel filed Form 4 for Peak Bio, Inc. on 18 Nov 2024.
Change
- Previous filing in this sequence was filed on 16 Feb 2024.
- Current net transaction value: -$275,500.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
PKBO
transaction
Common Stock
Conversion of derivative security
- Transaction value
- Shares
- +763,316
- Change %
- Price
- Shares after
- 763,316
- Date
- 14 Nov 2024
- Ownership
- Direct
- Footnotes
- F1, F2
PKBO
transaction
Common Stock
Disposed to Issuer
- Transaction value
- Shares
- -763,316
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 14 Nov 2024
- Ownership
- Direct
- Footnotes
- F1, F3
PKBO
transaction
Common Stock
Disposed to Issuer
- Transaction value
- Shares
- -67,735
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 14 Nov 2024
- Ownership
- See footnote
- Footnotes
- F1, F3, F4
PKBO
transaction
Common Stock
Disposed to Issuer
- Transaction value
- Shares
- -68,891
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 14 Nov 2024
- Ownership
- See footnote
- Footnotes
- F1, F3, F5
PKBO
transaction
Common Stock
Disposed to Issuer
- Transaction value
- Shares
- -47,364
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 14 Nov 2024
- Ownership
- See footnote
- Footnotes
- F1, F3, F6
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
PKBO
transaction
Derivative
Convertible Notes
Conversion of derivative security
- Transaction value
- $275,500
- Shares
- Change %
- Price
- Shares after
- 0
- Date
- 14 Nov 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 763,316
- Exercise price
- Footnotes
- F1, F2
PKBO
transaction
Derivative
Stock Option (Right to Buy)
Disposed to Issuer
- Transaction value
- $0
- Shares
- -400,000
- Change %
- -100%
- Price
- $0.000000
- Shares after
- 0
- Date
- 14 Nov 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 400,000
- Exercise price
- $0.8000
- Footnotes
- F1, F7
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 7 footnotes
Footnote F1
This Form 4 reports securities transacted pursuant to the terms of the Agreement and Plan of Merger, dated as of March 4, 2024, as amended (the "Merger Agreement"), by and among the Issuer, Akari Therapeutics Plc ("Parent"), and Pegasus Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer effective as of November 14, 2024, with the Issuer surviving as a wholly owned subsidiary of Parent (the "Merger").
Footnote F2
Immediately prior to the effective time of the Merger (the "Effective Time"), the principal amount of convertible promissory notes held by the Reporting Person (together with accrued interest thereon) automatically converted into shares of common stock of the Issuer ("Peak Common Stock").
Footnote F3
At the Effective Time, each issued and outstanding share of Peak Common Stock was cancelled and converted into the right to receive 0.2935 (the "Exchange Ratio") American Depositary Shares ("ADSs") of Parent, each ADS representing a number of ordinary shares, par value $0.0001 per share (the "Ordinary Shares") of Parent.
Footnote F4
The securities are held by QuestBio LLC. The Reporting Person is managing member of the LLC and has sole dispositive power over the shares.
Footnote F5
The securities are held by Davis Island Ventures, LLC. The Reporting Person is managing member of the LLC and has sole dispositive power over the shares.
Footnote F6
The securities are held by Innovative Lifesci Investments, LLC. The Reporting Person is managing member of the LLC and has sole dispositive power over the shares.
Footnote F7
At the Effective Time, each option to purchase shares of Peak Common Stock ("Peak Option") that was outstanding immediately prior to the Effective Time and unexercised, whether or not vested, was assumed by Parent and converted into the option to purchase a number of Ordinary Shares or ADSs (any such option, an "Assumed Option") equal to the number of Peak Common Stock underlying each such Peak Option multiplied by the Exchange Ratio.